IRIDEX CORP Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by IRIDEX Corporation on September 6, 2007. The filing reports material corporate governance changes, specifically the resignation of a director and the appointment of a new director in connection with a recent securities purchase agreement.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The only financial figure disclosed relates to a capital transaction: the Company sold $5 million of securities to purchasers identified as "BlueLine" under a Securities Purchase Agreement dated August 31, 2007.
Material Changes
- Director Resignation: Robert K. Anderson resigned from the Board of Directors and the Compensation and Nominating Committee effective September 6, 2007.
- Director Appointment: William M. Moore was appointed to the Board of Directors effective September 6, 2007, pursuant to the rights granted to BlueLine Partners LLC under the August 31, 2007 Securities Purchase Agreement.
- Board Composition Rights: BlueLine received the right to designate two individuals for appointment to the Board. Mr. Moore is the discretionary designee. The Company agreed to nominate these designees for reelection as long as BlueLine holds Series A Preferred Stock.
Compensatory Arrangements and Outlook
In connection with his appointment, William M. Moore received the following compensatory arrangements under the Company's 1998 Stock Plan:
- Initial Grant: A non-qualified stock option to purchase 15,000 shares of common stock. The grant is effective September 31, 2007 (note: date likely intended as October 1, 2007, or a typo in source), with an exercise price equal to the fair market value on that date.
- Vesting Schedule: The initial 15,000 shares vest over 36 months (1/36th per month).
- Annual Grant: Mr. Moore will automatically receive an option to purchase 5,000 shares upon his annual reelection to the Board. These shares vest over 12 months (1/12th per month).
- Term: Options have a term of 7 years unless terminated earlier.
The filing contains no specific guidance, outlook, or discussion of risks beyond the standard disclosure of the transaction terms.
Key Facts for Investor Verification
- Verify the exact effective date of the stock option grant, as the filing text states "September 31, 2007," which is not a valid calendar date.
- Confirm the total number of shares authorized for issuance under the 1998 Stock Plan to assess the dilution impact of the new grants.
- Review the full terms of the August 31, 2007 Securities Purchase Agreement to understand the rights attached to the Series A Preferred Stock held by BlueLine.
- Check subsequent filings to confirm if the second director seat designated by BlueLine has been filled.